Nuformix (LON:NFX) Announces Earnings Results

Nuformix (LON:NFX) posted its quarterly earnings results on Thursday. The company reported GBX (0.02) EPS for the quarter, Digital Look Earnings reports.

Nuformix Stock Up 3.0%

NFX opened at GBX 0.17 on Friday. Nuformix has a 12-month low of GBX 0.01 and a 12-month high of GBX 0.56. The stock has a market cap of £4.44 million, a price-to-earnings ratio of -4.33 and a beta of 1.55. The business has a 50 day moving average of GBX 0.18 and a 200-day moving average of GBX 0.23.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.